Showing 5021-5030 of 9403 results for "".
- New Time-Limited Double Allē Points Promotion Launched for Juvederm Usershttps://practicaldermatology.com/news/new-double-alle-points-promotion-for-juvederm-users/2461307/Consumers can earn double points in Allē, Allergan Aesthetics' loyalty rewards program, when treated with two or three syringes from the JUVÉDERM Collection of Fillers during the same visit. Allē points can be redeemed for future Allē-eligible treatments or products.&nb
- Joe Jonas Named New Xeomin Brand Partnerhttps://practicaldermatology.com/news/joe-jonas-named-new-xeomin-brand-partner/2461305/Joe Jonas is the latest Xeomin (incobotulinumtoxinA) brand partner, Merz Aesthetics announced. The U.S. partnership with Jonas kicks off a new ‘Beauty on Your Terms’ campaign for Xeomin and represents the first time the singer, songwr
- CDC: People with Acne, AD, PsO, and Other Active Exfoliative Skin Conditions at Higher Risk for Severe Monkeypoxhttps://practicaldermatology.com/news/cdc-people-with-acne-ad-pso-and-other-active-exfoliative-skin-conditions-at-higher-risk-for-severe-monkeypox/2461303/People with active exfoliative skin conditions are at higher risk for severe Monkeypox, according to interim clinical guidance from the federal Centers for Disease Control and Prevention. Many people infected with monkeypox virus have a
- Senté Launches Cysteamine HSA Pigment & Tone Correctorhttps://practicaldermatology.com/news/sente-launches-cysteamine-hsa-pigment-tone-corrector/2461301/Cysteamine HSA Pigment & Tone Corrector from Senté has launched to safely and effectively target pigmentation in all skin tones. The hydroquinone-free formula is safe for long-term use and formulated for all skin types, including dry or sensitive skin.
- La Roche-Posay, American Cancer Society Partner to Improve Patient and Caregiver Quality of Lifehttps://practicaldermatology.com/news/la-roche-posay-american-cancer-partner-to-improve-patient-and-caregiver-quality-of-life/2461299/La Roche-Posay US is joining forces with the American Cancer Society (ACS) to further the support of cancer patients, survivors, caregivers, and the oncology community as well as raise awareness of cancer treatments' skin side effects. Since 1905, La Roche-Posay has been committed to improvin
- Epidural Nerve Block with Lidocaine Leads to Clearance of Psoriatic Skin Lesionshttps://practicaldermatology.com/news/epidural-nerve-block-with-lidocaine-leads-to-clearance-of-psoriatic-skin-lesions/2461297/Use of an epidural nerve block with lidocaine leads to clearance of psoriatic skin lesions, according to a novel proof-of-concept study in the Journal of Investigative Dermatology. “Case studies have shown that psoriasis patients have experienced significant symptom
- Aesthetics Biomedical Inc. Receives Third U.S. Patent for “Biological Preserving Composition and Methods of Use” for SoME Skincare Product Linehttps://practicaldermatology.com/news/aesthetics-biomedical-inc-receives-third-us-patent-for-biological-preserving-composition-and-methods-of-use-for-its-some-skincare-product-line/2461296/Aesthetics Biomedical Inc. scored its third U.S. patent for “biological preserving composition and methods of use” for its SoME skincare product line. The patent covers topical compositions for combining biologics with skincare preserving the exclusivity of SoME Skincar
- Expert FDA Panel Recommends Skin Lesion Analyzers and Apps for Skin Cancer Detection Keep Class III Statushttps://practicaldermatology.com/news/expert-fda-panel-recommends-skin-lesion-analyzers-and-apps-for-skin-cancer-detection-keep-class-iii-status/2461293/The FDA held a meeting with the Medical Devices Advisory Committee in late July to gather expert advice on the regulation of AI driven, skin lesion analyzers (SLAs) and Apps for skin cancer detection. Panel members urged caution for skin cancer detection SLAs and Apps and stressed the need for mo
- Arcutis Completes Enrollment in Pivotal Phase 3 Roflumilast AD Trialhttps://practicaldermatology.com/news/arcutis-completes-enrollment-in-pivotal-phase-3-roflumilast-ad-trial/2461290/Arcutis Biotherapeutics, Inc. has completed enrollment of the last subject in its INTEGUMENT-1 pivotal Phase 3 trial of roflumilast cream 0.15% in adults and children with atopic dermatitis (AD). Roflumilast cream is a once daily topical formulation of roflumilast, a highly potent and s
- Pulse Biosciences Scores FDA 510(k) Clearance of Expanded Energy Settings for CellFX Systemhttps://practicaldermatology.com/news/pulse-biosciences-scores-fda-510k-clearance-of-expanded-energy-settings-for-cellfx-system/2461289/The U.S. Food and Drug Administration (FDA) gave 510(k) clearance tp expanded energy settings for use with Pulse Biosciences, Inc.’s CellFX System treatments tips in dermatology. “Pulse Biosciences is dedicated to providing dermatologists a superior solution for the treatmen